We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

HemoSonics Demonstrates Breakthrough in Point-Of-Care Viscoelastic Hemostasis Testing

By LabMedica International staff writers
Posted on 01 Aug 2024

At ADLM 2024, HemoSonics (Durham, NC, USA) is demonstrating its Quantra Hemostasis System which has the broadest range of FDA-cleared indications for use in its category and is cleared for use with arterial and venous blood samples in cardiac, trauma, liver, and major orthopedic surgery patients.

HemoSonics' Quantra Hemostasis System consists of the Quantra Hemostasis Analyzer with QPlus and QStat Cartridges, which enable clinicians to deliver patient-centered decisions on bleeding management that improve care and optimize blood product usage. The Quantra System is FDA-cleared for use in point-of-care settings such as operating rooms, intensive care units, and in hospital laboratories, enabling hospitals to standardize use institution-wide with greater operational efficiency. The Quantra System allows healthcare professionals to make individualized and evidence-based decisions on how to manage a bleeding patient and give a patient only medically appropriate therapy – an approach that supports global initiatives to reduce inappropriate transfusions of blood products.


Image: FDA recently granted HemoSonics expanded use of its critical bleeding management system with Special 510(k) clearance (Photo courtesy of HemoSonics)
Image: FDA recently granted HemoSonics expanded use of its critical bleeding management system with Special 510(k) clearance (Photo courtesy of HemoSonics)

The Quantra System requires minimal resources to maintain, is easy to operate and interpret, and provides fast, comprehensive whole-blood coagulation analysis at the point of care or in laboratory-based settings, typically in less than 15 minutes. A recent study showed that the implementation of the Quantra Hemostasis Analyzer with the QPlus Cartridge reduced utilization of blood components by up to 90%, allowing greater availability for those patients truly in need. In addition, the cost of blood products decreased by 41%. HemoSonics' QStat Cartridge used with the Quantra Hemostasis Analyzer first received 510(k) clearance from the U.S. FDA in 2022 for use in venous whole blood samples. In April this year, HemoSonics received Special 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the expanded use of arterial blood samples with its Quantra QStat Cartridge.

Related Links:
HemoSonics


New
Gold Member
Troponin T QC
Troponin T Quality Control
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
H.pylori DNA Extraction Kit
Savvygen Stool NA Extraction Kit
New
Respiratory Syncytial Virus Test
QuickVue RSV Test

Latest ADLM 2024 News

EKF Diagnostics Showcases Range of Diabetes and Hematology POC Devices

Cytovale Demonstrates 8-Minute Sepsis Diagnostic Test

Inpeco Launches Next-Generation Total Lab Automation System